This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

NASH and fibrosis progression

Authoring team

Fibrosis Progression in NASH

Approximately 40% of NASH patients progress to fibrosis globally (1,2)

  • 5% and 10% of patients with NASH diagnosed on their initial biopsy will present with clinically significant fibrosis at this initial biopsy, and an additional 15-20% will progress to advanced fibrosis in less than a decade (2)
  • age and presence of inflammation on initial biopsy are independent predictors of progression to advanced fibrosis (3)

Reference:

  1. Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L,Wymer M. Global epidemiology of nonalcoholic fatty liver disease - meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology.2016;64(1):73-84
  2. Argo C, Northup P, Al-Osaimi A, Caldwell S. Systematic review of risk factors for fibrosis progressionin non-alcoholic steatohepatitis. J Hepatol. 2009;51(2):371-9.
  3. Hashimoto E, Tokushige K. Prevalence, gender,ethnic variations, and prognosis of NASH. J Gastroenterol. 2011;46(suppl 1):63–9.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.